The Maladaptive Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir) on the Rat Heart

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Reyskens, Kathleen M S E ^a   Fisher, Tarryn Lee ^a   Schisler, Jonathan C ^b   O'Connor, Wendi G ^b   Rogers, Arlin B ^b   Willis, Monte S ^b   Planesse, Cynthia ^c   Rondeau, Philippe ^c   Bourdon, Emmanuel ^c   Essop, M Faadiel ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITÉ DE LA RÉUNION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACETYL COENZYME A CARBOXYLASE BETA; ADENOSINE TRIPHOSPHATASE; ALCOHOL; CHOLESTEROL; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEASOME; SUPEROXIDE; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UBIQUITIN; UNCLASSIFIED DRUG; CALCINEURIN; CALCIUM BINDING PROTEIN; CONNEXIN 43; DRUG COMBINATION; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; PHOSPHOLAMBAN; PRIMER DNA; RITONAVIR; TRANSCRIPTION FACTOR NFAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; CARDIOTOXICITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; EX VIVO STUDY; FATTY ACID OXIDATION; GENE EXPRESSION REGULATION; HEART DISEASE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; INSULIN RESISTANCE; ISOLATED HEART; LIPID LIVER LEVEL; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; MITOCHONDRIAL ENERGY TRANSFER; MYOCARDIAL DISEASE; NONHUMAN; OSMOTIC PUMP; OXIDATIVE STRESS; RAT; REAL TIME POLYMERASE CHAIN REACTION; TISSUE LEVEL; TREATMENT DURATION; UPREGULATION; WEIGHT GAIN; ANALYSIS OF VARIANCE; ANIMAL; BLOOD; CARDIAC MUSCLE; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HIV INFECTIONS; LIVER; METABOLISM; PROCEDURES; WESTERN BLOTTING; WISTAR RAT; DRUG EFFECT; HEART MUSCLE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY;

ANALYSIS OF VARIANCE; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOTTING, WESTERN; CALCINEURIN; CALCIUM-BINDING PROTEINS; CHOLESTEROL, LDL; CONNEXIN 43; DNA PRIMERS; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; LIVER; LOPINAVIR; MALE; MYOCARDIUM; NFATC TRANSCRIPTION FACTORS; OXIDATIVE STRESS; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RITONAVIR; TRIGLYCERIDES;

EID: 84884785986     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073347     Document Type: Article

References (55)

1. World Health Organization (2011) Global HIV/AIDS response. Epidemic update and health sector progress towards Universal Access. Progress Report 2011.
2. Armstrong W, Calabrese L, Taege A, (2005) HIV update 2005: Origins, issues, prospects, and complications. Clev Clin J Med 72: 73-78.
3. Melekhin VV, Shepherd BE, Stinnette SE, Rebeiro PF, Barkanic G, et al. (2009) Antiretroviral therapy initiation before, during, or after pregnancy in HIV-1-infected women: maternal virologic, immunologic, and clinical response. PloS ONE 4: e6961.
4. Palella F, (1998) Human immunodeficiency virus infection. N Engl J Med 338: 853-860.
5. Panther LA, (2002) How HIV infection and its treatment affects the cardiovascular system: what is known, what is needed. Am J Physiol- Heart Circ Physiol 283: H1-H4.
6. Carr A, Samaras K, Chisholm DJ, Cooper DA, (1998) Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351: 1881-1883.
7. Carr A, Samaras K, Burton S, Law M, Freund J, et al. (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58.
8. Hui DY, (2003) Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res 42: 81-92.
9. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, et al. (2008) State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation 118: 198-210.
10. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm D, et al. (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099.
11. Gan S, Samaras K, Thompson C, Kraegen E, Carr A, et al. (2002) Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related Lipodystrophy. Diabetes 51: 3163-3169.
12. Rudich A, Ben-Romano R, Etzion S, Bashan N, (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 183: 75-88.
13. Friis-Møller N, Reiss P, Sabin CA, Weber R, Monforte AD, et al. (2007) Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 356: 1723-1735.
14. Mondy KE, Gottdiener J, Overton ET, Henry K, Bush T, et al. (2011) High prevalence of echocardiographic abnormalities among HIV-infected persons in the era of highly active antiretroviral therapy. Clin Infec Dis 52: 378-386.
15. Becker A, Sliwa K, Stewart S, Libhaber E, Essop A, et al. (2010) Acute coronary syndromes in treatment- naive black South Africans with human immunodeficiency virus infection. J Interven Cardiol 23: 70-77.
16. Lekakis J, Tsiodras S, Ikonomidis I, Palios J, Poulakou G, et al. (2008) HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Science 115: 189-196.
17. Macho A, Castedo M, Marchetti P, Aguilar JJ, Decaudin D, et al. (1995) Mitochondrial dysfunctions in circulating T lymphocytes from human immunodeficiency virus-1 carriers. Blood 86: 2481-2487.
18. Greenspan HC, Aruoma OI, (1994) Oxidative stress and apoptosis in HIV infection: a role for plant-derived metabolites with synergistic antioxidant activity. Immunol Today 15: 209-213.
19. Jiang B, Hebert VY, Li Y, Mathis JM, Alexander JS, et al. (2007) HIV antiretroviral drug combination induces endothelial mitochondrial dysfunction and reactive oxygen species production, but not apoptosis. Toxicol Appl Pharmacol 224: 60-71.
20. Matarrese P, Gambardella L, Cassone A, Vella S, Cauda R, et al. (2003) Mitochondrial membrane hyperpolarization hijacks activated T lymphocytes toward the apoptotic-prone phenotype: homeostatic mechanisms of HIV protease inhibitors. J Immunol 170: 6006-6015.
21. Riddle TM, Kuhel DG, Woollett LA, Fichtenbaum CJ, Hui DY, (2001) HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 276: 37514-37519.
22. Eberlé D, Hegarty B, Bossard P, Ferré P, Foufelle F, (2004) SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86: 839-848.
23. Vallett SM, Sanchez HB, Rosenfeld JM, Osborne TF, Biol TFJ, et al. (1996) A direct role for sterol regulatory element binding protein in activation of 3-hydroxy-3-methylglutaryl coenzyme A reductase gene. J Biol Chem 271: 12247-12253.
24. Schmidtke G, Holzhütter H, Bogyo M, Kairies N, Groll M, et al. (1999) How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 274: 35734-35740.
25. Liang J-S, Distler O, Cooper D, Jamil H, Deckelbaum R, et al. (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: A potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7: 1327-1331.
26. Punga T, Bengoechea-Alonso MT, Ericsson J, (2006) Phosphorylation and ubiquitination of the transcription factor sterol regulatory element-binding protein-1 in response to DNA binding. J Biol Chem 281: 25278-25286.
27. Hirano Y, Yoshida M, Shimizu M, Sato R, (2001) Direct demonstration of rapid degradation of nuclear sterol regulatory element-binding proteins by the ubiquitin-proteasome pathway. J Biol Chem 276: 36431-36437.
28. Darley-Usmar VM, Ball LE, Chatham JC, (2012) Protein O-linked β-N-acetylglucosamine: a novel effector of cardiomyocyte metabolism and function. J Mol Cell Cardiol 52: 538-549.
29. Mapanga R, Rajamani U, Dlamini N, Zungu-Edmondson M, Kelly-Laubscher R, et al. (2012) Oleanolic acid: a novel cardioprotective agent that blunts hyperglycemia-induced contractile dysfunction. PloS One 7: e47322.
30. Cacho J, Sevillano J, de Castro J, Herrera E, Ramos MP, (2008) Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats. Am J Physiol- Endocrinol Metab 295: E1269-E1276.
31. Boudina S, Sena S, O'Neill BT, Tathireddy P, Young ME, et al. (2005) Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112: 2686-2695.
32. Aebi H, (1984) Catalase in vitro. Methods Enzymol 105: 121-126.
33. Levine R, Wehr N, Williams J, Stadtman E, Shacter E, (2000) Determination of carbonyl groups in oxidized proteins. Methods Mol Biol 99: 15-24.
34. Willis MS, Schisler JC, Li L, Rodríguez JE, Hilliard EG, et al. (2009) Cardiac muscle ring finger-1 increases susceptibility to heart failure in vivo. Circ Res 105: 80-88.
35. Willis MS, Ike C, Li L, Wang D-Z, Glass DJ, et al. (2007) Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 100: 456-459.
36. Andersen CL, Jensen JL, Ørntoft TF, (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 64: 5245-5250.
37. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3 research0034 (I-research0034) ():: II.
38. Hecker PA, Mapanga RF, Kimar CP, Ribeiro RF, Brown BH, et al. (2012) Effects of glucose-6-phosphate dehydrogenase deficiency on the metabolic and cardiac responses to obesogenic or high-fructose diets. Am J Physiol- Endocrinol Metab 303: E959-E972.
39. Andrews NC, Faller DV, (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499.
40. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346: 2039-2046.
41. Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman C, et al. (2008) Effects of boosted tipranavir and lopinavir on body composition, insulin sensitivity and adipocytokines in antiretroviral-naive adults. AIDS 22: 2313-2321.
42. Ferrer E, del Rio L, Martinez E, Curto J, Domingo P, et al. (2011) Impact of switching from Lopinavir/Ritonavir to Atazanavir/Ritonavir on body fat redistribution in virologically suppressed HIV-infected adults. Aids Res Hum Retrovir 27: 1061-1065.
43. Lagathu C, Kim M, Maachi M, Vigouroux C, Cervera P, et al. (2005) HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 87: 65-71.
44. Lekakis J, Tsiodras S, Ikonomidis I, Palios J, (2008) HIV-positive patients treated with protease inhibitors have vascular changes resembling those observed in atherosclerotic cardiovascular disease. Clin Science 196: 189-196.
45. Lo J, Abbara S, Shturman L, Soni A, Wei J, et al. (2010) Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography agiography in HIV-infected men. AIDS 24: 243-253.
46. Bernal E, Marín I, Muñoz A, Sabán J, Sarabia F, et al. (2012) Hypertriglyceridemic waist phenotype is a risk factor fo subclinical atherosclerosis in human immunodeficiency virus-infected patients. Med Clin 139: 561-565.
47. Jerico C, Knobel H, Calvo N, Sorli M, Guelar A, et al. (2006) Subclinical carotid atherosclerosis in HIV-infected patients: a role of combination antirtroviral therapy. Stroke 37: 812-817.
48. Puigserver P, (2005) Tissue-specific regulation of metabolic pathways through the transcriptional coactivator PGC1-alpha. Intl J Obes 29: S5-S9.
49. Spiegelman B, (2007) Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. Novartis Found Symp 287: 60-63.
50. Farhoud M, Nijtmans L, Wanders R, Wessels H, Lasonder E, et al. (2012) Impaired ubiquitin-proteasome-mediated PGC-1α protein turnover and induced mitochondrial biogenesis secondary to complex-I deficiency. Proteomics 12: 1349-1362.
51. Trausch-Azar J, Leone TC, Kelly DP, Schwartz AL, (2010) Ubiquitin proteasome-dependent degradation of the transcriptional coactivator PGC-1α via the N-terminal pathway. J Biol Chem 285: 40192-40200.
52. Taylor EB, Rutter J, (2011) Mitochondrial quality control by the ubiquitin-proteasome system. Biochem Soc Transact 39: 1509-1513.
53. Jeon HB, Choi ES, Yoon JH, Hwang JH, Chang JW, et al. (2007) A proteomics approach to identify the ubiquitinated proteins in mouse heart. Biochem Biophys Res Commun 357: 731-736.
54. Vernochet C, Azoulay S, Duval D, Guedj R, Cottrez F, et al. (2005) Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 280: 2238-2243.
55. Sivitz W, Yorek M, (2010) Mitochondrial dysfunction in diabetes: from molecular mechanisms to functional significance and therapeutic opportunities. Antiox Redox Signal 12: 1-41.